Immune T cells can transfer and boost anti-breast cancer immunity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immune T cells can transfer and boost anti-breast cancer immunity

Published:2018-08-27 Issue:12 Volume:7 Page:e1500672
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Thakur Archana¹,Rathore Ritesh²,Kondadasula Sri Vidya³,Uberti Joseph P.³,Ratanatharathorn Voravit³,Lum Lawrence G.¹

Affiliation:

1. Department of Medicine, Division of Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA, USA

2. Department of Hematology and Oncology, Roger Williams Hospital, Providence, RI, USA

3. Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, MI, USA

Funder

HHS | NIH | National Cancer Institute

Susan G. Komen for the Cure

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1500672

Reference21 articles.

1. Use of Anti-CD3 × Anti-HER2/neu Bispecific Antibody for Redirecting Cytotoxicity of Activated T Cells Toward HER2/neu+Tumors

2. Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial

3. High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials

4. IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments

5. Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer;Cancer Research Communications;2024-06-10

2. Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells;Journal for ImmunoTherapy of Cancer;2024-03

3. Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide;Journal of Neuro-Oncology;2024-01

4. Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells;2023-11-09

5. Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity;Frontiers in Immunology;2023-08-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3